SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study
The U.S. National Institutes of Health (NIH) will utilize SciBase's electrical impedance spectroscopy technology as a primary endpoint in a new study examining the skin barrier.
Swedish company SciBase Holding AB announced that the U.S. National Institutes of Health (NIH) and the Swiss Institute of Allergy and Asthma Research (SIAF) will initiate a collaborative study utilizing SciBase's Nevisense device and its Electrical Impedance Spectroscopy (EIS) technology. The study, named THREAT (Testing Harms Related to Exposure to Allergenic Toxins), aims to investigate the impact of environmental exposures on the skin.
The NIH has selected skin impedance, measured by SciBase's EIS technology, as the primary endpoint for assessing skin barrier dysfunction. This research design has been detailed in an editorial published in the peer-reviewed journal Allergy. The study will involve 80 healthy volunteers exposed to common irritants such as sodium lauryl sulfate (SLS), synthetic fibers, or natural fibers like cotton.
EIS measures the opposition to electrical flow, reflecting the skin barrier's functional status. These measurements will be used alongside molecular, microbiome, and inflammatory biomarkers to track changes in skin barrier function over time. The selection of EIS as a primary endpoint underscores its scientific validity as an objective method for skin barrier assessment.
"We are pleased that our Nevisense technology has been selected for this important NIH-led research initiative," said Pia Renaudin, CEO of SciBase. "The use of skin impedance as a primary endpoint highlights the scientific relevance of EIS in assessing skin barrier function and represents an important step in expanding our technology's role in dermatology and skin health research."